Longer follow-up from the phase 3 AMBASSADOR trial showed adjuvant pembrolizumab to demonstrate a statistically significant ...

The combination of ramucirumab with trifluridine/tipiracil failed to show improvements in overall survival vs TAS-102 alone ...

Patients with platinum-sensitive relapsed ovarian cancer given maintenance olaparib/cediranib had similar progression-free ...

0:09 | NKT-2152 is a HIF-2α inhibitor, so it will bind to HIF-2α to prevent heterodimerization with HIF-1 beta. And this is ...

In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to ...

In an updated analysis of the phase 3 CheckMate 77T study, perioperative nivolumab showed event-free survival benefits for ...

Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer ...

The novel ROS1 inhibitor zidesamtinib demonstrated promising early activity in heavily pretreated patients with advanced ROS1 ...

Meredith McKean, MD, discusses a longer-term follow-up study investigating fianlimab and cemiplimab immunotherapy in advanced ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

A statistically significant improvement in progression-free survival and objective response rate was seen with belzutifan ...

Ruxolitinib can cause cytopenia, the most prominent adverse event (AE). There are rates of anemia and thrombocytopenia in ...